
| September 27, 2025 | December 31, 2024 | |||||||||||||
| Assets | ||||||||||||||
| Current assets | ||||||||||||||
| Cash and cash equivalents | $ | 428,684 | $ | 196,589 | ||||||||||
| Short-term investments | 19,650 | — | ||||||||||||
Accounts receivable, net of allowances of $1,923 and $2,701, respectively | 116,053 | 278,582 | ||||||||||||
| Inventories, net | 229,887 | 216,472 | ||||||||||||
| Prepaid expenses | 18,394 | 20,203 | ||||||||||||
| Income tax receivable | 2,548 | 6,426 | ||||||||||||
| Other current assets | 20,569 | 48,697 | ||||||||||||
| Total current assets | 835,785 | 766,969 | ||||||||||||
Property, plant, and equipment, net of accumulated depreciation of $121,814 and $112,099, respectively | 158,234 | 160,377 | ||||||||||||
| Goodwill | 949,952 | 943,645 | ||||||||||||
| Trademark | 736,000 | 736,000 | ||||||||||||
| Customer relationships, net | 183,296 | 198,333 | ||||||||||||
| Other intangibles, net | 88,274 | 96,095 | ||||||||||||
| Other non-current assets | 84,079 | 89,205 | ||||||||||||
| Total assets | $ | 3,035,620 | $ | 2,990,624 | ||||||||||
Liabilities and Stockholders’ Equity | ||||||||||||||
| Current liabilities | ||||||||||||||
| Current portion of long-term debt | $ | 13,413 | $ | 13,991 | ||||||||||
| Accounts payable | 68,766 | 81,476 | ||||||||||||
| Accrued expenses and other liabilities | 180,286 | 217,242 | ||||||||||||
| Income taxes payable | — | 273 | ||||||||||||
| Total current liabilities | 262,465 | 312,982 | ||||||||||||
| Long-term debt, net | 947,744 | 950,562 | ||||||||||||
| Deferred tax liabilities, net | 238,893 | 239,111 | ||||||||||||
| Other non-current liabilities | 63,732 | 64,322 | ||||||||||||
| Total liabilities | 1,512,834 | 1,566,977 | ||||||||||||
Stockholders’ equity | ||||||||||||||
Preferred stock, $0.001 par value, 100,000,000 authorized, no shares issued or outstanding as of September 27, 2025 and December 31, 2024 | — | — | ||||||||||||
Common stock $0.001 par value, 750,000,000 authorized; 245,717,477 issued and 217,051,108 outstanding at September 27, 2025; 244,444,889 issued and 215,778,520 outstanding at December 31, 2024 | 246 | 245 | ||||||||||||
| Additional paid-in capital | 1,105,018 | 1,093,468 | ||||||||||||
Common stock in treasury; 28,666,369 and 28,666,369 at September 27, 2025 and December 31, 2024, respectively | (359,274) | (358,133) | ||||||||||||
| Retained earnings | 782,724 | 699,564 | ||||||||||||
| Accumulated other comprehensive income | (5,928) | (11,497) | ||||||||||||
Total stockholders’ equity | 1,522,786 | 1,423,647 | ||||||||||||
Total liabilities and stockholders’ equity | $ | 3,035,620 | $ | 2,990,624 | ||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| September 27, 2025 | September 28, 2024 | September 27, 2025 | September 28, 2024 | |||||||||||||||||||||||
| Net sales | $ | 244,336 | $ | 227,569 | $ | 772,780 | $ | 724,531 | ||||||||||||||||||
| Cost of sales | 119,200 | 114,474 | 376,430 | 361,770 | ||||||||||||||||||||||
| Gross profit | 125,136 | 113,095 | 396,350 | 362,761 | ||||||||||||||||||||||
| Selling, general and administrative expense | 69,803 | 64,509 | 206,813 | 187,678 | ||||||||||||||||||||||
| Research, development and engineering expense | 7,122 | 6,449 | 19,236 | 18,870 | ||||||||||||||||||||||
| Acquisition and restructuring related expense | 276 | 1,145 | 3,767 | 2,488 | ||||||||||||||||||||||
| Amortization of intangible assets | 6,882 | 7,576 | 20,587 | 21,425 | ||||||||||||||||||||||
| Operating income | 41,053 | 33,416 | 145,947 | 132,300 | ||||||||||||||||||||||
| Interest expense, net | 11,316 | 13,209 | 38,617 | 48,600 | ||||||||||||||||||||||
| Loss on debt extinguishment | — | — | — | 4,926 | ||||||||||||||||||||||
| Other expense (income), net | (1,469) | (705) | (1,996) | (1,989) | ||||||||||||||||||||||
| Total other expense | 9,847 | 12,504 | 36,621 | 51,537 | ||||||||||||||||||||||
| Income from operations before income taxes | 31,206 | 20,912 | 109,326 | 80,763 | ||||||||||||||||||||||
| Provision for income taxes | 7,178 | 4,411 | 26,166 | 16,841 | ||||||||||||||||||||||
| Net income | $ | 24,028 | $ | 16,501 | $ | 83,160 | $ | 63,922 | ||||||||||||||||||
| Earnings per share | ||||||||||||||||||||||||||
| Basic | $ | 0.11 | $ | 0.08 | $ | 0.38 | $ | 0.30 | ||||||||||||||||||
| Diluted | $ | 0.11 | $ | 0.07 | $ | 0.37 | $ | 0.29 | ||||||||||||||||||
| Weighted average common shares outstanding | ||||||||||||||||||||||||||
| Basic | 216,826,626 | 215,231,886 | 216,395,032 | 214,836,643 | ||||||||||||||||||||||
| Diluted | 222,420,881 | 221,436,206 | 222,074,267 | 221,251,355 | ||||||||||||||||||||||
Hayward Holdings, Inc. Unaudited Condensed Consolidated Statements of Cash Flows (In thousands) | Nine Months Ended | |||||||||||||
| September 27, 2025 | September 28, 2024 | |||||||||||||
| Cash flows from operating activities | ||||||||||||||
| Net income | $ | 83,160 | $ | 63,922 | ||||||||||
| Adjustments to reconcile net income to net cash used in operating activities | ||||||||||||||
| Depreciation | 17,026 | 13,929 | ||||||||||||
| Amortization of intangible assets | 25,808 | 26,299 | ||||||||||||
| Amortization of deferred debt issuance fees | 2,818 | 3,248 | ||||||||||||
| Stock-based compensation | 9,821 | 7,299 | ||||||||||||
| Deferred income taxes (benefit) | 1,949 | (8,344) | ||||||||||||
| Allowance for credit losses | (1,021) | (62) | ||||||||||||
| Loss on debt extinguishment | — | 4,926 | ||||||||||||
| (Gain) loss on sale of property, plant and equipment | 381 | (451) | ||||||||||||
| Changes in operating assets and liabilities | ||||||||||||||
| Accounts receivable | 168,754 | 173,400 | ||||||||||||
| Inventories | (8,064) | (4,204) | ||||||||||||
| Other current and non-current assets | 29,913 | (6,203) | ||||||||||||
| Accounts payable | (14,002) | 2,871 | ||||||||||||
| Accrued expenses and other liabilities | (33,566) | (868) | ||||||||||||
| Net cash provided by operating activities | 282,977 | 275,762 | ||||||||||||
| Cash flows from investing activities | ||||||||||||||
| Purchases of property, plant, and equipment | (19,822) | (16,153) | ||||||||||||
| Software development costs | (1,579) | (1,399) | ||||||||||||
| Acquisitions, net of cash acquired | — | (61,636) | ||||||||||||
| Proceeds from sale of property, plant, and equipment | — | 311 | ||||||||||||
| Purchases of short-term investments | (19,650) | — | ||||||||||||
| Proceeds from short-term investments | — | 25,000 | ||||||||||||
| Net cash used in investing activities | (41,051) | (53,877) | ||||||||||||
| Cash flows from financing activities | ||||||||||||||
| Proceeds from issuance of long-term debt | — | 2,886 | ||||||||||||
| Payments of long-term debt | (6,941) | (129,971) | ||||||||||||
| Proceeds from issuance of short-term notes payable | — | 6,340 | ||||||||||||
| Payments of short-term notes payable | (2,169) | (4,676) | ||||||||||||
| Debt issuance costs | (1,388) | — | ||||||||||||
| Purchase of common stock | (1,141) | — | ||||||||||||
| Other, net | 719 | (427) | ||||||||||||
| Net cash used in financing activities | (10,920) | (125,848) | ||||||||||||
| Effect of exchange rate changes on cash and cash equivalents | 1,089 | 50 | ||||||||||||
| Change in cash and cash equivalents | 232,095 | 96,087 | ||||||||||||
| Cash and cash equivalents, beginning of period | 196,589 | 178,097 | ||||||||||||
| Cash and cash equivalents, end of period | $ | 428,684 | $ | 274,184 | ||||||||||
| Supplemental disclosures of cash flow information: | ||||||||||||||
| Cash paid-interest | $ | 39,892 | $ | 47,965 | ||||||||||
| Cash paid-income taxes | 20,587 | 26,853 | ||||||||||||
| Non-cash investing and financing activities: | ||||||||||||||
Accrued and unpaid purchases of property, plant, and equipment | 1,064 | 1,862 | ||||||||||||
| Equipment financed under finance leases | 1,866 | 843 | ||||||||||||
| (Dollars in thousands) | Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||
| September 27, 2025 | September 28, 2024 | September 27, 2025 | September 28, 2024 | |||||||||||||||||||||||
| Net income | $ | 24,028 | $ | 16,501 | $ | 83,160 | $ | 63,922 | ||||||||||||||||||
| Depreciation | 5,509 | 4,862 | 17,026 | 13,929 | ||||||||||||||||||||||
| Amortization | 8,642 | 9,253 | 25,808 | 26,299 | ||||||||||||||||||||||
| Interest expense, net | 11,316 | 13,209 | 38,617 | 48,600 | ||||||||||||||||||||||
| Income taxes | 7,178 | 4,411 | 26,166 | 16,841 | ||||||||||||||||||||||
| Loss on debt extinguishment | — | — | — | 4,926 | ||||||||||||||||||||||
| EBITDA | 56,673 | 48,236 | 190,777 | 174,517 | ||||||||||||||||||||||
Stock-based compensation (a) | — | 136 | 57 | 556 | ||||||||||||||||||||||
Currency exchange items (b) | (536) | (344) | 236 | (470) | ||||||||||||||||||||||
Acquisition and restructuring related expense, net (c) | 276 | 1,145 | 3,767 | 2,488 | ||||||||||||||||||||||
Other (d) | 2,653 | 1,920 | 1,567 | 1,657 | ||||||||||||||||||||||
| Total Adjustments | 2,393 | 2,857 | 5,627 | 4,231 | ||||||||||||||||||||||
| Adjusted EBITDA | $ | 59,066 | $ | 51,093 | $ | 196,404 | $ | 178,748 | ||||||||||||||||||
| Net income margin | 9.8 | % | 7.3 | % | 10.8 | % | 8.8 | % | ||||||||||||||||||
| Adjusted EBITDA margin | 24.2 | % | 22.5 | % | 25.4 | % | 24.7 | % | ||||||||||||||||||
| (a) | Represents non-cash stock-based compensation expense related to equity awards issued to management, employees, and directors. The adjustment includes only expense related to awards issued under the 2017 Equity Incentive Plan, which were awards granted prior to the effective date of Hayward’s initial public offering (the “IPO”). | |||||||
| (b) | Represents unrealized non-cash (gains) losses on foreign denominated monetary assets and liabilities and foreign currency contracts. | |||||||
| (c) | Adjustments in the three months ended September 27, 2025 are primarily driven by $0.3 million of costs related to restructuring actions in E&RW. Adjustments in the three months ended September 28, 2024 are primarily driven by $0.7 million of transaction and integration costs associated with the acquisition of the ChlorKing business and $0.4 million of costs to finalize actions initiated in prior years. Adjustments in the nine months ended September 27, 2025 are primarily driven by $3.3 million of transaction and integration costs associated with the acquisition of the ChlorKing business, $0.5 million of costs related to restructuring actions in E&RW and $0.2 million of separation costs for the consolidation of operations in North America, partially offset by a reduction in expense of $0.2 million to finalize the relocation of the Company's corporate office functions to Charlotte, North Carolina from Berkeley Heights, New Jersey. Adjustments in the nine months ended September 28, 2024 are primarily driven by $1.3 million of transaction and integration costs associated with the acquisition of ChlorKing, $0.7 million of separation and other costs associated with the centralization and consolidation of operations in Europe and $0.4 million of costs to finalize actions initiated in prior years. | |||||||
| (d) | Adjustments in the three months ended September 27, 2025 primarily include a $2.8 million non-recurring litigation expense. Expense beyond the $2.8 million will be paid by the Company's insurance carriers pursuant to the Company's retention amount with its insurance carriers. Other adjustments include $0.2 million of income from insurance proceeds related to flood damage associated with a hurricane at a contract manufacturing facility. Adjustments in the three months ended September 28, 2024 are primarily driven by a $1.6 million non-cash increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business and $0.3 million of costs incurred related to litigation. Adjustments in the nine months ended September 27, 2025 primarily include a $2.8 million non-recurring litigation expense. Expense beyond the $2.8 million will be paid by the Company's insurance carriers pursuant to the Company's retention amount with its insurance carriers. Other adjustments include $1.3 million of income from insurance proceeds related to flood damage associated with a hurricane at a contract manufacturing facility. Adjustments in the nine months ended September 28, 2024 are primarily driven by a $1.6 million non-cash increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business and $0.5 million of costs incurred related to litigation, partially offset by $0.5 million of gains on the sale of assets. | |||||||
| (Dollars in thousands) | Last Twelve Months(e) | Fiscal Year | ||||||||||||
| September 27, 2025 | December 31, 2024 | |||||||||||||
| Net income | $ | 137,893 | $ | 118,655 | ||||||||||
| Depreciation | 23,175 | 20,078 | ||||||||||||
| Amortization | 35,292 | 35,783 | ||||||||||||
| Interest expense, net | 52,180 | 62,163 | ||||||||||||
| Income taxes | 34,852 | 25,527 | ||||||||||||
| Loss on debt extinguishment | — | 4,926 | ||||||||||||
| EBITDA | 283,392 | 267,132 | ||||||||||||
Stock-based compensation (a) | 109 | 608 | ||||||||||||
Currency exchange items (b) | (130) | (836) | ||||||||||||
Acquisition and restructuring related expense, net (c) | 7,743 | 6,464 | ||||||||||||
Other (d) | 3,989 | 4,079 | ||||||||||||
| Total Adjustments | 11,711 | 10,315 | ||||||||||||
| Adjusted EBITDA | $ | 295,103 | $ | 277,447 | ||||||||||
| Net income margin | 12.5 | % | 11.3 | % | ||||||||||
| Adjusted EBITDA margin | 26.8 | % | 26.4 | % | ||||||||||
| (a) | Represents non-cash stock-based compensation expense related to equity awards issued to management, employees, and directors. The adjustment includes only expense related to awards issued under the 2017 Equity Incentive Plan, which were awards granted prior to the effective date of the IPO. | |||||||
| (b) | Represents unrealized non-cash (gains) losses on foreign denominated monetary assets and liabilities and foreign currency contracts. | |||||||
| (c) | Adjustments in the last twelve months ended September 27, 2025 primarily include $6.3 million of compensation expenses for the retention of key employees acquired in the ChlorKing acquisition. Pursuant to the ChlorKing acquisition agreement, this $6.3 million was an employee retention payment that was deposited into an escrow account on the date of acquisition. The full amount held in escrow was to be released to the specified key employees if such employees are employed by Hayward on the one-year anniversary of the acquisition. These payments were contingent on continued employment and are not dependent on the achievement of any metric or performance measure. The retention costs were recognized over the twelve-month period from the date of acquisition. Further, other adjustments include $1.1 million of termination benefits related to a reduction-in-force within E&RW, $0.3 million of facility and other costs related to a restructuring action within E&RW and $0.2 million of separation costs associated with the consolidation of operations in North America, partially offset by a reduction in expense of $0.2 million to finalize the relocation of the Company's corporate headquarters to Charlotte, North Carolina. Adjustments in the year ended December 31, 2024 are primarily driven by $3.2 million of compensation expenses for the retention of key employees acquired in the ChlorKing acquisition. Pursuant to the ChlorKing acquisition agreement, this $3.2 million was part of a total $6.3 million employee retention payment that was deposited into an escrow account on the date of acquisition. The full amount held in escrow will be released to the specified key employees if such employees are employed by Hayward on the one-year anniversary of the acquisition. These payments are contingent on continued employment and are not dependent on the achievement of any metric or performance measure. The retention costs will be recognized over the twelve-month period from the date of acquisition. Further, other adjustments for the year ended December 31, 2024 include $1.1 million of transaction and integration costs associated with the acquisition of the ChlorKing business, $0.9 million of termination benefits related to a reduction-in-force within E&RW, $0.8 million of separation and other costs associated with the centralization and consolidation of operations in Europe and $0.4 million of costs to finalize restructuring actions initiated in prior years. | |||||||
| (d) | Adjustments in the last twelve months ended September 27, 2025 are primarily driven by a $2.8 million non-recurring litigation expense, a $1.6 million increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business partially offset by $0.6 million of net insurance settlement proceeds which reflects costs incurred of $0.7 million offset by $1.3 million of insurance proceeds related to flood damage associated with a hurricane at a contract manufacturing facility. Adjustments in the year ended December 31, 2024 are primarily driven by a $3.3 million increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business, $0.7 million of costs sustained from flood damage associated with a hurricane at a contract manufacturing facility and $0.5 million of costs incurred related to litigation, partially offset by $0.5 million of gains on the sale of assets. | |||||||
| (e) | Items for the last twelve months ended September 27, 2025 are calculated by adding the items for the nine months ended September 27, 2025 plus fiscal year ended December 31, 2024 and subtracting the items for the nine months ended September 28, 2024. | |||||||
(Dollars in thousands, except per share data) | Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||
| September 27, 2025 | September 28, 2024 | September 27, 2025 | September 28, 2024 | |||||||||||||||||||||||
| Net income | $ | 24,028 | $ | 16,501 | $ | 83,160 | $ | 63,922 | ||||||||||||||||||
Tax adjustments (a) | (481) | (451) | (673) | (2,203) | ||||||||||||||||||||||
| Other adjustments and amortization: | ||||||||||||||||||||||||||
Stock-based compensation (b) | — | 136 | 57 | 556 | ||||||||||||||||||||||
Currency exchange items (c) | (536) | (344) | 236 | (470) | ||||||||||||||||||||||
Acquisition and restructuring related expense, net (d) | 276 | 1,145 | 3,767 | 2,488 | ||||||||||||||||||||||
Other (e) | 2,653 | 1,920 | 1,567 | 1,657 | ||||||||||||||||||||||
| Total other adjustments | 2,393 | 2,857 | 5,627 | 4,231 | ||||||||||||||||||||||
| Loss on debt extinguishment | — | — | — | 4,926 | ||||||||||||||||||||||
| Amortization | 8,642 | 9,253 | 25,808 | 26,299 | ||||||||||||||||||||||
Tax effect (f) | (2,708) | (2,815) | (7,717) | (8,360) | ||||||||||||||||||||||
| Adjusted net income | $ | 31,874 | $ | 25,345 | $ | 106,205 | $ | 88,815 | ||||||||||||||||||
| Weighted average number of common shares outstanding, basic | 216,826,626 | 215,231,886 | 216,395,032 | 214,836,643 | ||||||||||||||||||||||
| Weighted average number of common shares outstanding, diluted | 222,420,881 | 221,436,206 | 222,074,267 | 221,251,355 | ||||||||||||||||||||||
| Basic EPS | $ | 0.11 | $ | 0.08 | $ | 0.38 | $ | 0.30 | ||||||||||||||||||
| Diluted EPS | $ | 0.11 | $ | 0.07 | $ | 0.37 | $ | 0.29 | ||||||||||||||||||
| Adjusted basic EPS | $ | 0.15 | $ | 0.12 | $ | 0.49 | $ | 0.41 | ||||||||||||||||||
| Adjusted diluted EPS | $ | 0.14 | $ | 0.11 | $ | 0.48 | $ | 0.40 | ||||||||||||||||||
| (a) | Tax adjustments for the three and nine months ended September 27, 2025 reflect a normalized tax rate of 24.5% and 24.5%, respectively, compared to the Company’s effective tax rate of 23.0% and 23.9%, respectively. The Company’s effective tax rate for the three and nine months ended September 27, 2025 primarily includes the tax benefits resulting from stock compensation. Tax adjustments for the three and nine months ended September 28, 2024 reflect a normalized tax rate of 23.2% and 22.5%, respectively, compared to the Company's effective tax rate of 21.1% and 20.9%, respectively. The Company’s effective tax rate for the three months ended September 28, 2024 includes the tax benefits resulting from stock compensation and the nine months ended September 28, 2024 additionally includes a tax benefit resulting from a return-to-provision adjustment. | |||||||
| (b) | Represents non-cash stock-based compensation expense related to equity awards issued to management, employees, and directors. The adjustment includes only expense related to awards issued under the 2017 Equity Incentive Plan, which were awards granted prior to the effective date of the IPO. | |||||||
| (c) | Represents unrealized non-cash (gains) losses on foreign denominated monetary assets and liabilities and foreign currency contracts. | |||||||
| (d) | Adjustments in the three months ended September 27, 2025 are primarily driven by $0.3 million of costs related to restructuring actions in E&RW. Adjustments in the three months ended September 28, 2024 are primarily driven by $0.7 million of transaction and integration costs associated with the acquisition of the ChlorKing business and $0.4 million of costs to finalize actions initiated in prior years. Adjustments in the nine months ended September 27, 2025 are primarily driven by $3.3 million of transaction and integration costs associated with the acquisition of the ChlorKing business, $0.5 million of costs related to restructuring actions in E&RW and $0.2 million of separation costs for the consolidation of operations in North America, partially offset by a reduction in expense of $0.2 million to finalize the relocation of the Company's corporate office functions to Charlotte, North Carolina from Berkeley Heights, New Jersey. Adjustments in the nine months ended September 28, 2024 are primarily driven by $1.3 million of transaction and integration costs associated with the acquisition of ChlorKing, $0.7 million of separation and other costs associated with the centralization and consolidation of operations in Europe and $0.4 million of costs to finalize actions initiated in prior years. | |||||||
| (e) | Adjustments in the three months ended September 27, 2025 primarily include a $2.8 million non-recurring litigation expense. Expense beyond the $2.8 million will be paid by the Company's insurance carriers pursuant to the Company's retention amount with its insurance carriers. Other adjustments include $0.2 million of income from insurance proceeds related to flood damage associated with a hurricane at a contract manufacturing facility. Adjustments in the three months ended September 28, 2024 are primarily driven by a $1.6 million non-cash increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business and $0.3 million of costs incurred related to litigation. Adjustments in the nine months ended September 27, 2025 primarily include a $2.8 million non-recurring litigation expense. Expense beyond the $2.8 million will be paid by the Company's insurance carriers pursuant to the Company's retention amount with its insurance carriers. Other adjustments include $1.3 million of income from insurance proceeds related to flood damage associated with a hurricane at a contract manufacturing facility. Adjustments in the nine months ended September 28, 2024 are primarily driven by a $1.6 million non-cash increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business and $0.5 million of costs incurred related to litigation, partially offset by $0.5 million of gains on the sale of assets. | |||||||
| (f) | The tax effect represents the immediately preceding adjustments at the normalized tax rates as discussed in footnote (a) above. | |||||||
| (Dollars in thousands) | Three Months Ended | Three Months Ended | ||||||||||||||||||||||||
| September 27, 2025 | September 28, 2024 | |||||||||||||||||||||||||
| NAM | E&RW | NAM | E&RW | |||||||||||||||||||||||
| Segment income | $ | 55,387 | $ | 6,247 | $ | 51,569 | $ | 2,475 | ||||||||||||||||||
| Depreciation | 4,675 | 441 | 4,404 | 271 | ||||||||||||||||||||||
| Amortization | 1,760 | — | 1,677 | — | ||||||||||||||||||||||
| Stock-based compensation | — | — | 107 | — | ||||||||||||||||||||||
Other (a) | (101) | — | 1,704 | — | ||||||||||||||||||||||
| Total adjustments | 6,334 | 441 | 7,892 | 271 | ||||||||||||||||||||||
| Adjusted segment income | $ | 61,721 | $ | 6,688 | $ | 59,461 | $ | 2,746 | ||||||||||||||||||
| Segment income margin % | 26.6 | % | 17.3 | % | 26.4 | % | 7.6 | % | ||||||||||||||||||
| Adjusted segment income margin % | 29.6 | % | 18.5 | % | 30.5 | % | 8.4 | % | ||||||||||||||||||
| (a) | The three months ended September 27, 2025 includes $0.1 million of insurance proceeds related to flood damage associated with a hurricane at a contract manufacturing facility. The three months ended September 28, 2024 primarily includes a $1.6 million non-cash increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business. | |||||||
| (Dollars in thousands) | Nine Months Ended | Nine Months Ended | ||||||||||||||||||||||||
| September 27, 2025 | September 28, 2024 | |||||||||||||||||||||||||
| NAM | E&RW | NAM | E&RW | |||||||||||||||||||||||
| Segment income | $ | 182,215 | $ | 20,374 | $ | 166,646 | $ | 16,800 | ||||||||||||||||||
| Depreciation | 14,623 | 1,294 | 12,619 | 791 | ||||||||||||||||||||||
| Amortization | 5,221 | — | 4,874 | — | ||||||||||||||||||||||
| Stock-based compensation | — | — | 176 | 10 | ||||||||||||||||||||||
Other (a) | (611) | — | 1,723 | — | ||||||||||||||||||||||
| Total adjustments | 19,233 | 1,294 | 19,392 | 801 | ||||||||||||||||||||||
Adjusted segment income | $ | 201,448 | $ | 21,668 | $ | 186,038 | $ | 17,601 | ||||||||||||||||||
| Segment income margin % | 28.0 | % | 16.7 | % | 27.3 | % | 14.6 | % | ||||||||||||||||||
Adjusted segment income margin % | 31.0 | % | 17.7 | % | 30.5 | % | 15.3 | % | ||||||||||||||||||
| (a) | The nine months ended September 27, 2025 primarily includes $0.6 million of insurance proceeds related to flood damage associated with a hurricane at a contract manufacturing facility. The nine months ended September 28, 2024 primarily includes a $1.6 million non-cash increase in cost of goods sold resulting from the fair value inventory step-up adjustment recognized as part of the purchase accounting for the acquisition of the ChlorKing business. | |||||||